Understanding the impact of bone turnover on heavy metal toxicity and how to manage chelation therapy safely.

By Paul Anderson

Acute and ongoing exposures should be assessed and identified to the degree possible before starting heavy metal chelation. Sources of acute and ongoing metal exposure may include exposure via food, drink, respiratory, skin, and others. Bone turnover can also cause metals to be released from bone and appear on heavy metal testing.

Any person at risk for increased bone turnover should be screened before heavy metal chelation for bone turnover. This allows a safe chelation procedure and appropriate consent, reducing the risk of chelating metals from active bone turnover.

Data shows lower levels of metals (blood or urine) are associated with lower levels of osteopenia and osteoporosis.^5,8 This is because people with more significant bone turnover have more release of metals from bone. Heavy metals are also associated with lower bone mineral density.¹³

Questions:

1. Is this a problem? (What is the propensity of heavy metals to be incorporated into bone?)
2. Who should be assessed (What are the average ages and comorbid health issues to consider before testing bone turnover)?

Problems?

Many references support the pathologic effect of heavy metals becoming incorporated into bone. Two papers reviewed for this update include one that affirms bone uptake of toxicant metals and outlines the variety of pathogenic effects toxicant metals have on bone.¹¹ The other paper used bone biopsies with metal assays from 65 patients, including two pathological groups and a health control group.¹³ This paper found higher heavy metals in the pathological (osteoporotic) groups and a likely causal connection between heavy metals and osteoporosis.

Who Should Be Screened?

Age and comorbidity are additional considerations in who we decide to add bone turnover screening before chelation therapy. Clinicians are generally trained that peak bone mineral density is reached in the second decade and begins to degrade in the third and fourth decades. Indeed, in healthy individuals, decreases in bone mineral density do start in the early to middle forties in men and women.¹² Based on available data, screening for increased bone turnover in healthy men and women starting in their forties would be wise. Other factors besides age should be considered, which may lower the bone turnover screening age.

The two main categories (beyond age) are inflammatory and chronic diseases and medication-induced bone loss:

• Inflammatory and other diseases can trigger bone loss at any age.³ Some studies include children with rheumatological or other inflammatory conditions as young as 13.⁷
• Medication-induced bone loss is more widespread than is often considered. An enlightening quote from a review paper helps to show the initial scope¹⁰: “While glucocorticoids (GCs) are most commonly associated with drug-induced osteoporosis, the use of several other therapeutic agents increase the risk of significant bone loss and fracture. These medications include: 
• proton pump inhibitors (PPIs), 
• selective serotonin receptor inhibitors (SSRIs), 
• thiazolidinediones (TZDs), 
• anticonvulsants, 
• medroxyprogesterone acetate (MPA), 
• hormone deprivation therapy, 
• calcineurin inhibitors, 
• chemotherapies, and 
• anticoagulants.” 

In addition, other papers¹⁵ have even broader pharmacological categories triggering bone density loss.

Why is Screening Critical?

If the chelation process begins with increased bone turnover and net loss, you will have high metals on the testing as long as the patient is alive (as you are speeding metal elimination from the bone). Unless you stop or slow the bone turnover, you will never chelate them appropriately as you pull heavy metals and nutrient minerals out while the bones are unstable. 

To oppose these dangers requires:

• Bone turnover assessment
• Supportive detox
• Bone support slows bone turnover and cleans up metals as they move out of the bone.

Who should we test for bone turnover before initiating chelation?

• All patients of any gender are in their forties and older.

• Any patient younger than their forties with a chronic disease, especially rheumatological or inflammatory diseases.
• Pediatric patients with rheumatological diagnoses or chronic inflammatory diseases.
• Patients of any age are on medications known to cause bone loss.
• Post-chemotherapy patients.
• Hyperthyroidism.

Monitoring:

Testing may show elevated lead (and other metals) if bone turnover is elevated, regardless of how long chelation therapy lasts. Elevated metals on a non-challenged urine toxic metals test, normed to NHANES¹⁶, will also be seen for the same reason. This has created trouble (legal and patient management) for practitioners who “chelated for months” only to find the lead and other metals never decreased.

While DEXA testing is recommended for benchmarking and managing osteopenia and osteoporosis, the requirements for assessing and managing a chelation patient may need to be more dynamic. Crosslink testing, such as NTx and CTX, is dynamic and easier to perform (and less costly) for the patient. If used as serial measures, they can track trends in bone turnover. NTx can be performed on urine or serum, whereas CTX is a serum test. The chosen test does not matter as long as the same test is used for serial testing through treatment and follow-up.

NTx – N-Telopeptide Cross-links (NTx), Urine (Serial Monitor) is available at most reference laboratories.

• Subsequent specimens for comparison should be collected at approximately the same time of day as the baseline specimen.
• The “NTx” in the example below (and reported by most labs) is the N-telo/Creat ratio (not the raw N-telopeptide value).
• The reference ranges for NTx in urine, as measured in BCE/mM creatinine, are as follows [Mayo Labs]: Male: 21-83, Female (premenopausal): 17-94, Female (postmenopausal): 26-124

In anyone (male or female) with suspected bone turnover (see list above), obtain an NTx (urine), and if greater than:

• 90 in a male
• 100 in a premenopausal female
• 130 in a postmenopausal female

Initiate bone health support (see below) and re-test every 6 months.

Elevated non-challenged urine toxic metals (over NHANES 95^th percentile) should have bone turnover in the differential diagnosis.

Carboxy-terminal collagen crosslinks (CTX) are an analogous test to NTx. NTx can be obtained via serum or urine, whereas CTX is typically serum only. As the goal is to test the rate of bone turnover on serial measurements to protect the patient during chelation, either test may be used. CTX and NTx are considered equally efficacious for this purpose.¹ In the therapeutic guidelines below, if CTX is used, simply substitute CTX for NTx, and the clinical process is the same.

NTx levels of elevation [Mayo Labs]:

Therapeutic Approaches to Lowering Bone Turnover:

Mild to moderate bone turnover elevation: 

• Consent / Procedure:
  • Chelation may be held until bone turnover is slowed. 
  • If chelation proceeds for any reason, the patient should consent to initiate detoxification and chelation as usual but acknowledge that bone health support will be added to the protocol. 
  • The patient must acknowledge the inclusion of baseline NTx and that a repeat NTx will be run at the first re-check of the Urine Toxic Metals (UTM) (Pre and Post challenge). 
  • All follow-up UTM are pre- and post-challenge, with the pre-challenge being normed to NHANES.

Marked bone turnover elevation: 

• Consent / Procedure:
  • If chelation therapy proceeds, follow the above.
    • Consent the patient that they must include aggressive bone support while chelating, and that follow-up NTx and UTM (Pre and Post UTM) are required for safety.
    • They should have consented that their UTM levels will likely stay high until the bone turnover is under control.
  • If chelation therapy is held temporarily:
    • Consent the patient and explain the dynamics of the bone release of heavy metals. It is recommended that baseline NTx (with pre/post-UTM) be performed and that bone health be treated aggressively for 3 months while gentle detoxification is supported.
      • This can include glutathione, fiber, bowel regularity, and low weekly doses of oral DMSA to “mop up” circulating metals. 
• For this purpose, the author usually gives 250 – 500 mg DMSA orally and QHS two nights a week. 

It is critical to notify the patient of the dynamics and that they cannot expect metal levels on the UTM to decrease until bone turnover stabilizes. Clinically, testing and monitoring are most critical.

Bone Support Ideas:

• Physical support [aka ‘Super Heavy/Super Slow’ workout programs] “Osteostrong” or “Perfect Workout” are examples.
• Vitamin D is Sufficient to keep 25(OH) and 1,25(OH) in the upper 50 – 75% of the normal range [See resources below]
• Vitamin K2: (MK-4) 45 – 90 mg / day [4] or (MK-7) 180 – 250 mcg / day⁶
• Vitamin C, Ca/Mg/Zn, etc. (Any other nutrients as clinically indicated).
• Boron 3-6 mg QD
• Strontium Citrate 500-700 mg BID^9,14**
• Bisphosphonate Rx, if indicated²
• Appropriate hormone replacement therapy

** The use of high-dose strontium citrate is indicated in non-responsive bone loss.

Dr. Anderson is a recognized educator and clinician in integrative and naturopathic medicine with a focus on complex chronic illness and cancer. In addition to three decades of clinical experience, he was head of the interventional arm of a US-NIH-funded human research trial using IV and integrative therapies in cancer patients. He founded Advanced Medical Therapies in Seattle, Washington, a clinic focusing on cancer and chronic diseases. He now collaborates with clinics and hospitals in the US and other countries. His former positions included multiple medical school posts, as well as being a professor of pharmacology and clinical medicine at Bastyr University and chief of IV services for Bastyr Oncology Research Center.  

References

1.       Australian Journal for General Practitioners. Bone turnover markers. May, 2013. VOL 42-No 5, pages 285—287. https://www.racgp.org.au/afp/2013/may/bone-turnover-markers –NTX versus CTX?

2.       Eom S-Y, Yim D-H, Hong S-M, et al. Changes in blood and urinary cadmium levels and bone mineral density according to osteoporosis medication in individuals with an increased cadmium body burden. Human & Experimental Toxicology. 2018;37(4):350-357. doi:10.1177/0960327117705425

3.       Hanna B, Sakiniene E, Gjertsson I, Pullerits R, Jin T. Osteopenia/osteoporosis develops in the early phase of disease in patients with idiopathic inflammatory myopathies. Scand J Rheumatol. 2021 Sep;50(5):398-401. doi: 10.1080/03009742.2021.1882558. Epub 2021 Apr 15. PMID: 33856955.

4.       Iwamoto J. Vitamin K₂ therapy for postmenopausal osteoporosis. Nutrients. 2014 May 16;6(5):1971-80. doi: 10.3390/nu6051971. PMID: 24841104; PMCID: PMC4042573.

5.       Jalili C, Kazemi M, Taheri E, Mohammadi H, Boozari B, Hadi A, Moradi S. Exposure to heavy metals and the risk of osteopenia or osteoporosis: a systematic review and meta-analysis. Osteoporosis Int. 2020 Sep;31(9):1671-1682. doi: 10.1007/s00198-020-05429-6. Epub 2020 May 2. PMID: 32361950.

6.       Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int. 2013 Sep;24(9):2499-507. doi: 10.1007/s00198-013-2325-6. Epub 2013 Mar 23. PMID: 23525894.

7.       Lien G, Flatø B, Haugen M, Vinje O, Sørskaar D, Dale K, Johnston V, Egeland T, Førre Ø. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum. 2003 Aug;48(8):2214-23. doi: 10.1002/art.11097. PMID: 12905475.

8.       Lim, Hee-sook & Lee, Hae-Hyeog & Kim, Tae-Hee & Lee, Bo-Ra. (2016). Relationship between Heavy Metal Exposure and Bone Mineral Density in Korean Adult. Journal of Bone Metabolism. 23. 223. 10.11005/jbm.2016.23.4.223.

9.       Marx D, Rahimnejad Yazdi A, Papini M, Towler M. A review of the latest insights into the mechanism of action of strontium in bone. Bone Rep. 2020 Apr 24;12:100273. doi: 10.1016/j.bonr.2020.100273. PMID: 32395571; PMCID: PMC7210412.

10.   Panday K, Gona A, Humphrey MB. Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014 Oct;6(5):185-202. doi: 10.1177/1759720X14546350. PMID: 25342997; PMCID: PMC4206646.      

11.   Rodríguez J, Mandalunis PM. A Review of Metal Exposure and Its Effects on Bone Health. J Toxicol. 2018 Dec 23;2018:4854152. doi: 10.1155/2018/4854152. PMID: 30675155; PMCID: PMC6323513.

12.   Rondanelli M, Gasparri C, Perdoni F, Riva A, Petrangolini G, Peroni G, Faliva MA, Naso M, Perna S. Bone Mineral Density Reference Values in 18- to 95-Year-Old Population in Lombardy Region, Italy. Am J Mens Health. 2022 Sep-Oct;16(5):15579883221119363. doi: 10.1177/15579883221119363. PMID: 36305327; PMCID: PMC9619280.

13.   Scimeca M, Feola M, Romano L, Rao C, Gasbarra E, Bonanno E, Brandi ML, Tarantino U. Heavy metals accumulation affects bone microarchitecture in osteoporotic patients. Environ Toxicol. 2017 Apr;32(4):1333-1342. doi: 10.1002/tox.22327. Epub 2016 Jul 27. PMID: 27464007.

14.   Taylor BA, Bezuhly M, Brace M, Carter M, Hong P. Effect of strontium citrate on bone consolidation during mandibular distraction osteogenesis. Laryngoscope. 2017 Jul;127(7):E212-E218. doi: 10.1002/lary.26623. Epub 2017 May 9. PMID: 28485552.

15.   Vestergaard P. Drugs Causing Bone Loss. Handb Exp Pharmacol. 2020;262:475-497. doi: 10.1007/164_2019_340. PMID: 31889220.16. Anderson, P. (2015). NHANES 2015 updates from the fourth report. Consult Dr. Anderson. https://www.consultdranderson.com/nhanes-2015-updates-from-the-fourth-report/